Advertisement
Screener

HALOZYME THERAPEUTICS, INC. (HALO) Graph

HALO Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $481.00M; Cost of revenue $79.17M; Research and development $27.66M; Selling, general and administrative $57.00M.
  • 2026-03-31: Revenue $376.71M; Cost of revenue $79.24M; Research and development $25.56M; Selling, general and administrative $57.88M.
  • 2025-12-31: Revenue $451.77M*; Cost of revenue $78.77M*; Research and development (m); Selling, general and administrative $77.03M*.
  • 2025-09-30: Revenue $354.26M; Cost of revenue $55.24M; Research and development $17.25M; Selling, general and administrative $46.09M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

HALO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$129.63MRoyalty$307.70MBulk R Hu PH20$59.62MCollaborativeAgreements$43.67MDevice LicensingAnd Development$2.47MDevice PartneredProducts$14.58MEvent Based Development AndRegulatory Milestone And Other Fees$5.71MProprietaryProducts Sales$55.43MSales Based Milestone$0.00Upfront Fees$35.50MRevenue$481.00MCost of revenue$79.17MOperating income$287.65MOther income, net$2.84MResearch & development$27.66MSelling, general& administrative$57.00MPre-tax income$284.90MNet income$229.91M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$481.00M$79.17M$27.66M$57.00M(m)$54.99M$229.91M
2026-03-31$376.71M$79.24M$25.56M$57.88M(m)$30.28M$150.05M
2025-12-31$451.77M*$78.77M*(m)$77.03M*(m)$40.74M*-$141.59M*
2025-09-30$354.26M$55.24M$17.25M$46.09M(m)$43.73M$175.22M
2025-06-30$325.72M$46.36M$17.54M$41.61M(m)$39.78M$165.16M
2025-03-31$264.86M$48.40M$14.80M$42.36M(m)$25.73M$118.09M
2024-09-30$290.08M$49.43M$18.46M$41.24M(m)$28.14M$137.01M
2024-06-30$231.35M$39.61M$21.04M$35.71M(m)$24.50M$93.25M
2024-03-31$195.88M$28.33M$19.11M$35.13M(m)$19.20M$76.82M
2023-09-30$216.03M$54.82M$17.32M$35.27M(m)$19.92M$81.84M
2023-06-30$221.04M$50.07M$19.73M$38.95M(m)$18.40M$74.75M
2023-03-31$162.14M$35.17M$17.98M$37.36M(m)$12.62M$39.62M
2022-09-30$208.98M$47.32M$16.70M$34.47M(m)$12.07M$61.63M
2022-06-30$152.37M$33.94M$15.48M$57.48M(m)$7.33M$22.68M
2022-03-31$117.28M$15.92M$11.85M$13.83M(m)$14.30M$60.11M
2021-09-30$115.83M$18.59M$8.49M$13.17M(m)-$142.48M$216.59M
2021-06-30$136.46M$23.02M$8.07M$12.32M(m)$58.00K$91.46M
2021-03-31$89.02M$18.22M$9.01M$11.06M(m)$191.00K$27.89M
2020-12-31$121.70M(m)(m)(m)$44.08M(m)$73.16M
2020-09-30$65.32M$5.57M$7.75M$11.70M$25.02M$63.00K$36.21M
2020-06-30$55.22M$5.74M$8.95M$10.97M$25.67M$58.00K$25.82M
2020-03-31$25.35M$5.79M$10.16M$12.63M$28.58M$11.00K-$6.10M
2019-12-31$53.66M(m)(m)(m)$85.73M(m)-$34.40M
2019-09-30$46.23M$22.33M$30.45M$17.98M$70.77M$13.00K-$25.02M
2019-06-30$39.15M$1.88M$33.91M$17.34M$53.13M$17.00K-$14.62M
2019-03-31$56.95M$4.65M$31.33M$18.01M$53.98M$22.00K$1.80M
2018-12-31$60.23M(m)(m)(m)$60.30M(m)-$2.13M
2018-09-30$25.56M$626.00K$35.54M$14.86M$51.03M$0.00-$27.85M
2018-06-30$35.20M$836.00K$40.09M$14.35M$55.27M$33.00K-$22.89M
2018-03-31$30.87M$3.05M$37.98M$13.56M$54.58M$187.00K-$27.46M
2017-12-31$189.56M(m)(m)(m)$63.63M(m)$123.88M
2017-09-30$63.73M(m)$33.99M$13.33M$55.65M$580.00K$2.75M
2017-06-30$33.75M(m)$38.34M$13.10M$59.23M$180.00K-$30.76M
2017-03-31$29.57M(m)$36.94M$12.62M$57.09M$210.00K-$32.90M
2016-12-31$39.00M(m)(m)(m)$61.58M(m)-$27.39M
2016-09-30$31.85M(m)$33.86M$11.60M$54.60M$1.28M-$28.95M
2016-06-30$33.34M(m)$35.53M$11.22M$55.06M$300.00K-$26.88M
2016-03-31$42.50M(m)$40.10M$10.81M$58.67M$0.00-$19.82M
2015-12-31$39.00M(m)(m)(m)(m)(m)-$27.39M
2015-09-30$31.85M(m)$27.61M$10.23M(m)$0.00-$28.95M
2015-06-30$33.34M(m)$21.20M$9.81M(m)$0.00-$26.88M
2015-03-31$42.50M(m)$16.68M$9.40M(m)(m)-$19.82M
2014-12-31$30.38M(m)(m)(m)(m)(m)-$5.27M
2014-09-30$14.61M(m)$19.90M$8.59M(m)(m)-$20.28M
2014-06-30$18.39M(m)$18.65M$8.75M(m)(m)-$16.27M
2014-03-31$11.97M(m)$21.41M$10.25M(m)(m)-$26.55M
2013-12-31$12.50M(m)(m)(m)(m)(m)-$21.99M
2013-09-30$16.01M(m)$25.69M$8.13M(m)(m)-$19.29M
2013-06-30$14.45M(m)$27.99M$7.30M(m)(m)-$22.91M
2013-03-31$11.83M(m)$22.03M$7.56M(m)(m)-$19.29M
2012-12-31$21.79M(m)(m)(m)(m)(m)-$4.41M
2012-09-30$5.33M(m)$19.50M$5.63M(m)(m)-$20.01M
2012-06-30$7.76M(m)$16.08M$5.58M(m)(m)-$14.02M
2012-03-31$7.44M(m)$15.89M$6.62M(m)(m)-$15.12M
2011-12-31$2.41M(m)(m)(m)(m)(m)-$18.42M
2011-09-30$22.94M(m)$13.51M$4.26M(m)(m)$5.17M
2011-06-30$23.19M(m)$15.35M$4.57M(m)(m)$3.12M
2011-03-31$7.54M(m)$13.79M$3.41M(m)(m)-$9.64M
2010-09-30$3.40M(m)$12.45M$3.37M(m)(m)-$12.41M
2010-06-30$3.21M(m)$11.92M$3.36M(m)(m)-$12.15M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$857.71M$158.41M$53.22M$114.88M$85.27M$379.96M
2025-06-30$590.58M$94.76M$32.34M$83.98M$65.51M$283.25M
2024-06-30$427.23M$67.94M$40.15M$70.84M$43.70M$170.07M
2023-06-30$383.18M$85.24M$37.71M$76.31M$31.02M$114.37M
2022-06-30$269.64M$49.87M$27.34M$71.31M$21.63M$82.79M
2021-06-30$225.48M$41.24M$17.08M$23.38M$249.00K$119.35M
2020-06-30$80.58M$11.53M$19.11M$23.61M$69.00K$19.71M
2019-06-30$96.10M$6.53M$65.24M$35.34M$39.00K-$12.83M
2018-06-30$66.07M$3.89M$78.06M$27.91M$220.00K-$50.35M
2017-06-30$63.32M(m)$75.27M$25.72M$390.00K-$63.66M
2016-06-30$75.83M(m)$75.63M$22.03M$300.00K-$46.69M
2015-06-30$62.05M(m)$37.88M$19.21M$0.00-$12.09M
2014-06-30$30.35M(m)$40.06M$19.00M(m)-$42.82M
2013-06-30$26.29M(m)$50.02M$14.86M(m)-$42.20M
2012-06-30$15.20M(m)$31.97M$12.20M(m)-$29.14M
2011-06-30$30.73M(m)$29.13M$7.97M(m)-$6.52M
2010-06-30$6.66M(m)$23.39M$7.11M(m)-$23.94M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$944.84M$150.00M$49.59M$130.06M$109.24M$458.48M
2024-09-30$717.32M$117.36M$58.61M$112.09M$71.84M$307.08M
2023-09-30$599.21M$140.06M$55.03M$111.57M$50.95M$196.21M
2022-09-30$478.62M$97.18M$44.04M$105.78M$33.70M$144.43M
2021-09-30$341.31M$59.83M$25.56M$36.55M-$142.23M$335.94M
2020-09-30$145.89M$17.09M$26.86M$35.31M$132.00K$55.92M
2019-09-30$142.33M$28.86M$95.69M$53.32M$52.00K-$37.84M
2018-09-30$91.63M$4.51M$113.60M$42.77M$220.00K-$78.20M
2017-09-30$127.05M(m)$109.27M$39.05M$970.00K-$60.91M
2016-09-30$107.69M(m)$109.49M$33.63M$1.58M-$75.64M
2015-09-30$82.83M(m)$65.49M$29.44M$0.00-$36.55M
2014-09-30$44.96M(m)$59.97M$27.59M(m)-$63.10M
2013-09-30$42.30M(m)$75.71M$22.99M(m)-$61.49M
2012-09-30$20.53M(m)$51.48M$17.83M(m)-$49.15M
2011-09-30$53.68M(m)$42.65M$12.24M(m)-$1.35M
2010-09-30$10.05M(m)$35.84M$10.49M(m)-$36.35M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$1.40B$228.77M(m)$207.09M$149.99M$316.89M
2024-12-31$1.02B$159.42M$79.05M$154.34M$113.04M$444.09M
2023-12-31$829.25M$192.36M$76.36M$149.18M$66.73M$281.59M
2022-12-31$660.12M$139.30M$66.61M$143.53M$46.79M$202.13M
2021-12-31$443.31M$81.41M$35.67M$50.32M-$154.19M$402.71M
2020-12-31$267.59M$43.37M$34.24M$45.74M$217.00K$129.09M
2019-12-31$195.99M$45.55M$140.80M$77.25M-$11.00K-$72.24M
2018-12-31$151.86M$10.14M$150.25M$60.80M$537.00K-$80.33M
2017-12-31$316.61M$31.15M$150.64M$53.82M-$1.36M$62.97M
2016-12-31$146.69M(m)$150.84M$45.85M$1.16M-$103.02M
2015-12-31$135.06M(m)$93.24M$40.03M$0.00-$32.23M
2014-12-31$75.33M(m)$79.70M$35.94M$0.00-$68.38M
2013-12-31$54.80M(m)$96.64M$32.35M(m)-$83.48M
2012-12-31$42.33M(m)$70.04M$24.81M(m)-$53.55M
2011-12-31$56.09M(m)$57.56M$18.10M(m)-$19.77M
2010-12-31$13.62M(m)$51.77M$15.12M(m)-$53.24M
2009-12-31$13.67M(m)$56.61M$15.20M(m)-$58.36M

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78